NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

眼科藥市場成長機會、成長預測 (2020-2027年):各適應症、類型、劑型、通路、治療等級、地區

Ophthalmic Drugs Market by Indication, Type, Dosage Form, Distribution Channel, and Therapeutic Class : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 1009366
出版日期 內容資訊 英文 564 Pages
商品交期: 2-3個工作天內
價格
眼科藥市場成長機會、成長預測 (2020-2027年):各適應症、類型、劑型、通路、治療等級、地區 Ophthalmic Drugs Market by Indication, Type, Dosage Form, Distribution Channel, and Therapeutic Class : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2021年04月01日內容資訊: 英文 564 Pages
簡介

全球眼科藥的市場規模在預測期間內預計以5.6%的年複合成長率發展,從2019年的364億8848萬美元,成長到2027年581億3492萬美元的規模。

老年人口增加,青光眼,白內障,視網膜疾病,肌肉疾病等的眼科疾病的盛行率增加等要素促進該市場的成長。同時,副作用和開發的長期化預計抑制市場進一步成長。

本報告提供全球眼科藥的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的變化、預測,適應症、類型、劑型、銷售管道、治療等級、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特的五力分析
  • 主要企業的地位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析
  • COVID-19:影響分析

第4章 市場分析、預測:各適應症

  • 乾眼症
  • 青光眼
  • 感染疾病、發炎、過敏
  • 視網膜疾病
    • 濕性黃斑部病變
    • 乾燥性黃斑部病變
    • 糖尿病視網膜病變
    • 其他
  • 其他

第5章 市場分析、預測:各類型

  • 處方藥
  • 成藥
    • 市場規模、預測:各地區
    • 市場分析: 各國
    • 市場規模、預測:各劑型

第6章 市場分析、預測:各劑型

  • 液體點眼藥劑
  • 固態點眼藥劑
  • 半固態點眼藥劑
  • 多火車包廂藥物遞輸系統
  • 其他

第7章 市場分析、預測:各銷售通路

  • 醫院藥局
  • 藥妝店
  • 線上藥局
  • 其他
    • 市場規模、預測:各地區
    • 市場分析: 各國
    • 市場規模、預測:各劑型

第8章 市場分析、預測:各治療等級

  • 抗青光眼
  • 預防感染
  • 抗發炎
  • 抗過敏
  • 其他
    • 市場規模、預測:各地區
    • 市場分析: 各國
    • 市場規模、預測:各劑型

第9章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 中東
  • 北非
  • 其他地區

第10章 企業簡介

  • ABBVIE Inc.(ALLERGAN PLC)
  • Alcon, Inc.
  • BAUSCH & LOMB INCORPORATED
  • F. HOFFMANN-LA ROCHE LTD(GENENTECH, INC.)
  • NOVARTIS AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANTEN PHARMACEUTICAL CO., LTD
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.(ACTAVIS GENERICS)
目錄
Product Code: LI_17310 / A00220

The global ophthalmic drugs market was valued at $36,488.48 million in 2019, and is estimated to reach $58,134.92 million by 2027, registering a CAGR of 5.6% from 2020 to 2027. The eye is one of the most sensitive organ of the human body. Ophthalmic drugs are the formulations that are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration.

Growth of the global ophthalmic drugs market is majorly driven by a rise in geriatric population; alarming increase in the prevalence of eye disease such as glaucoma, cataract, retinal disease and muscular disease; and a surge in demand for ophthalmic drug for treatment of eye disease. For instance, according to the World Health Organization (WHO), in 2021, approximately 2.2 billion population was diagnosed with vision impairment across the globe. As per the statistics, the major cause of blindness and vision loss are cataracts and untreated refractive error for a longer period of time. Moreover, the geriatric population is more vulnerable to eye diseases due to aging effect the lens of eye become less flexible and decrease the ability to focus on an object. For instance, as per the data published by UN, 962 million population were present above the age of 60 years in 2017 which is expected to get double to nearly 2.1 billion by the year of 2050. It has been observed from the report of the American Academy of Ophthalmology, that there were 64.3 million people suffered from glaucoma in 2013, which increased to 76.0 million in 2020 and is expected to rise to 111.8 million by 2040. Thus, the rise in the geriatric population and increase in prevalence of glaucoma is expected to propel the demand for ophthalmic drugs, which, in turn, augments the market growth.

Furthermore, ophthalmic drugs play an important role in the global healthcare sector. Manufacturing of different dosage form of ophthalmic drugs such as drops, gel, and ointment is used for the treatment of a wide range of eye diseases. Moreover, rise in investment and activities in R&D by various healthcare sectors for development of new ophthalmic drugs, such as REFRESH DIGITAL lubricant eye drop (AbbVie Inc.) and CEQUA (Sun Pharmaceutical Ltd.), drive the growth of the global market. Upsurge in investment in R&D sector is a strategy of venture for the development of novel products and further aids to support the long-term growth of the business. In addition, rise in adoption of new technology is expected to provide lucrative opportunity for the expansion of the ophthalmic drugs market growth. For instance, in June 2020, Senju Pharmaceutical and Otsuka Pharmaceutical launched AILAMIDE, which is a novel combination ophthalmic solution used for treatment of glaucoma and ocular hypertension.

On the contrary, side effects associated with ophthalmic drugs and prolonged timelines for the development of efficient ophthalmic formulations is anticipated to hinder the market growth during the forecast period. For instance, Xalatan, which is prescribed for treatment of glaucoma, can also cause blurred vision, dry eye, and darkening of the eyelid. Moreover, the factors such as choice of excipients, buffers, maintaining the ideal pH and thickening agents lead to prolonged timelines for the development of ophthalmic drugs.

The ophthalmic drugs market is segmented into indication, type, dosage form, distribution channel, therapeutic class, and region. Depending on indication, the market is segmented into dry eye, glaucoma, infection/inflammation/allergy, retinal disorder, and others. The retinal disease segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others.

On the basis of type, the market is fragmented into the prescription drugs and over-the-counter-drugs. By dosage form, it is differentiated into liquid ophthalmic drug forms, solid ophthalmic drug forms, semi-solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per distribution channel, the market is classified into hospital pharmacies, drug stores, online pharmacies, and others. By therapeutic class, the global market is segregated into anti-glaucoma, anti-infection, anti-inflammation, anti-allergy, and others. On regional level, the ophthalmic drugs market is analyzed across North America, Europe, Asia-Pacific, Middle East, North-Africa, and Rest of World.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global ophthalmic drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ophthalmic drugs market

KEY MARKET SEGMENTS

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Wet Age-related Macular Degeneration
  • Dry Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Others
  • Others

By Type

  • Prescription Drugs
  • Over-the-counter Drugs

By Dosage Form

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Therapeutic Class

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others

By Region

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Poland
  • Rest of Europe
  • Asia-Pacific
  • Malaysia
  • Vietnam
  • Thailand
  • Philippines
  • Rest of Asia-Pacific
  • Middle East
  • UAE
  • South Arabia
  • Palestine
  • Jordan
  • Bahrain
  • Qatar
  • Azerbaijan
  • Georgia
  • Iraq
  • Pakistan
  • Kuwait
  • Israel
  • Kazakhstan
  • Uzbekistan
  • Tajikistan
  • Kyrgyzstan
  • Turkmenistan
  • Rest of Middle East
  • North Africa
  • Egypt
  • Morocco
  • Tunisia
  • Algeria
  • Lybia
  • Rest of North Africa
  • Rest of World
  • Brazil
  • Others

KEY MARKET PLAYERS

  • AbbVie Inc. (Allergan plc)
  • Alcon Inc.
  • Bausch & Lomb Incorporated
  • F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. (Actavis Generics)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of ophthalmic disorders
      • 3.5.1.2.Advancements in research and development in optometry
      • 3.5.1.3.Growth in geriatric population
      • 3.5.1.4.Increase in demand for the ophthalmic drugs
    • 3.5.2.Restraints
      • 3.5.2.1.Risks associated with ophthalmic drugs
      • 3.5.2.2.Longer timeline required for the formulation of ophthalmic drugs
    • 3.5.3.Opportunity
      • 3.5.3.1.Increase in research and developments by major key players
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the Ophthalmic Drug market

CHAPTER 4:OPHTHALMIC DRUGS MARKET, BY INDICATION

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Dry Eye
    • 4.2.1.Market size and forecast, by region
    • 4.2.2.Market analysis, by country
    • 4.2.3.Market size and forecast, by dosage form
  • 4.3.Glaucoma
    • 4.3.1.Market size and forecast, by region
    • 4.3.2.Market analysis, by country
    • 4.3.3.Market size and forecast, by dosage form
  • 4.4.Infection/Inflammation/Allergy
    • 4.4.1.Market size and forecast, by region
    • 4.4.2.Market analysis, by country
    • 4.4.3.Market size and forecast, by dosage form
  • 4.5.Retinal Disorders
    • 4.5.1.Market size and forecast, by type
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
    • 4.5.4.Market size and forecast, by dosage form
    • 4.5.5.Wet age-related macular degeneration
      • 4.5.5.1.Market size and forecast, by dosage form
    • 4.5.6.Dry age-related macular degeneration
      • 4.5.6.1.Market size and forecast, by dosage form
    • 4.5.7.Diabetic retinopathy
      • 4.5.7.1.Market size and forecast, by dosage form
    • 4.5.8.Other Retinal Disorders
      • 4.5.8.1.Market size and forecast, by dosage form
  • 4.6.Others
    • 4.6.1.Market size and forecast, by region
    • 4.6.2.Market analysis, by country
    • 4.6.3.Market size and forecast, by dosage form

CHAPTER 5:OPHTHALMIC DRUGS MARKET, BY TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Prescription Drugs
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
    • 5.2.3.Market size and forecast, by dosage form
  • 5.3.Over-The-Counter-Drugs
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
    • 5.3.3.Market size and forecast, by dosage form

CHAPTER 6:OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Liquid ophthalmic drug forms
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Solid ophthalmic drug forms
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Semisolid ophthalmic drug forms
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country
  • 6.5.Multicompartment drug delivery systems
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis, by country
  • 6.6.Other ophthalmic drug forms
    • 6.6.1.Market size and forecast, by region
    • 6.6.2.Market analysis, by country
  • 6.7.Dry Eye
    • 6.7.1.Market size and forecast, by region
    • 6.7.2.Market analysis, by country
    • 6.7.3.Market size and forecast, by dosage form
  • 6.8.Glaucoma
    • 6.8.1.Market size and forecast, by region
    • 6.8.2.Market analysis, by country
    • 6.8.3.Market size and forecast, by dosage form
  • 6.9.Infection/Inflammation/Allergy
    • 6.9.1.Market size and forecast, by region
    • 6.9.2.Market analysis, by country
    • 6.9.3.Market size and forecast, by dosage form
  • 6.10.Retinal Disorders
    • 6.10.1.Market size and forecast, by type
    • 6.10.2.Market size and forecast, by region
    • 6.10.3.Market analysis, by country
    • 6.10.4.Market size and forecast, by dosage form
    • 6.10.5.Wet age-related macular degeneration
      • 6.10.5.1.Market size and forecast, by dosage form
    • 6.10.6.Dry age-related macular degeneration
      • 6.10.6.1.Market size and forecast, by dosage form
    • 6.10.7.Diabetic retinopathy
      • 6.10.7.1.Market size and forecast, by dosage form
    • 6.10.8.Other Retinal Disorders
      • 6.10.8.1.Market size and forecast, by dosage form
  • 6.11.Others
    • 6.11.1.Market size and forecast, by region
    • 6.11.2.Market analysis, by country
    • 6.11.3.Market size and forecast, by dosage form

CHAPTER 7:OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Hospital Pharmacies
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market analysis, by country
    • 7.2.3.Market size and forecast, by dosage form
  • 7.3.Drug Stores
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market analysis, by country
    • 7.3.3.Market size and forecast, by dosage form
  • 7.4.Online Pharmacies
    • 7.4.1.Market size and forecast, by region
    • 7.4.2.Market analysis, by country
    • 7.4.3.Market size and forecast, by dosage form
  • 7.5.Others
    • 7.5.1.Market size and forecast, by region
    • 7.5.2.Market analysis, by country
    • 7.5.3.Market size and forecast, by dosage form

CHAPTER 8:OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.Anti-Glaucoma
    • 8.2.1.Market size and forecast, by region
    • 8.2.2.Market analysis, by country
    • 8.2.3.Market size and forecast, by dosage form
  • 8.3.Anti-infection
    • 8.3.1.Market size and forecast, by region
    • 8.3.2.Market analysis, by country
    • 8.3.3.Market size and forecast, by dosage form
  • 8.4.Anti-inflammatory
    • 8.4.1.Market size and forecast, by region
    • 8.4.2.Market analysis, by country
    • 8.4.3.Market size and forecast, by dosage form
  • 8.5.Anti-allergy
    • 8.5.1.Market size and forecast, by region
    • 8.5.2.Market analysis, by country
    • 8.5.3.Market size and forecast, by dosage form
  • 8.6.Others
    • 8.6.1.Market size and forecast, by region
    • 8.6.2.Market analysis, by country
    • 8.6.3.Market size and forecast, by dosage form

CHAPTER 9:OPHTHALMIC DRUGS MARKET, BY REGION

  • 9.1.Overview
    • 9.1.1.Market size and forecast
  • 9.2.North America
    • 9.2.1.North America market size and forecast, by indication
    • 9.2.2.North America market size and forecast, by type
    • 9.2.3.North America market size and forecast, by dosage form
    • 9.2.4.North America market size and forecast, by distribution channel
    • 9.2.5.North America market size and forecast, by therapeutic class
    • 9.2.6.North America market size and forecast, by country
    • 9.2.7.U.S.
      • 9.2.7.1.U.S. market size and forecast, by indication
      • 9.2.7.2.U.S. market size and forecast, by type
      • 9.2.7.3.U.S. market size and forecast, by dosage form
      • 9.2.7.4.U.S. market size and forecast, by distribution channel
      • 9.2.7.5.U.S. market size and forecast, by therapeutic class
    • 9.2.8.Rest of North America
      • 9.2.8.1.Rest of North America market size and forecast, by indication
      • 9.2.8.2.Rest of North America market size and forecast, by type
      • 9.2.8.3.Rest of North America market size and forecast, by dosage form
      • 9.2.8.4.Rest of North America market size and forecast, by distribution channel
      • 9.2.8.5.Rest of North America market size and forecast, by therapeutic class
  • 9.3.Europe
    • 9.3.1.Europe market size and forecast, by indication
    • 9.3.2.Europe market size and forecast, by type
    • 9.3.3.Europe market size and forecast, by dosage form
    • 9.3.4.Europe market size and forecast, by distribution channel
    • 9.3.5.Europe market size and forecast, by therapeutic class
    • 9.3.6.Europe market size and forecast, by country
    • 9.3.7.Germany
      • 9.3.7.1.Germany market size and forecast, by indication
      • 9.3.7.2.Germany market size and forecast, by type
      • 9.3.7.3.Germany market size and forecast, by dosage form
      • 9.3.7.4.Germany market size and forecast, by distribution channel
      • 9.3.7.5.Germany market size and forecast, by therapeutic class
    • 9.3.8.France
      • 9.3.8.1.France market size and forecast, by indication
      • 9.3.8.2.France market size and forecast, by type
      • 9.3.8.3.France market size and forecast, by dosage form
      • 9.3.8.4.France market size and forecast, by distribution channel
      • 9.3.8.5.France market size and forecast, by therapeutic class
    • 9.3.9.UK
      • 9.3.9.1.UK market size and forecast, by indication
      • 9.3.9.2.UK market size and forecast, by type
      • 9.3.9.3.UK market size and forecast, by dosage form
      • 9.3.9.4.UK market size and forecast, by distribution channel
      • 9.3.9.5.UK market size and forecast, by therapeutic class
    • 9.3.10.Italy
      • 9.3.10.1.Italy market size and forecast, by indication
      • 9.3.10.2.Italy market size and forecast, by type
      • 9.3.10.3.Italy market size and forecast, by dosage form
      • 9.3.10.4.Italy market size and forecast, by distribution channel
      • 9.3.10.5.Italy market size and forecast, by therapeutic class
    • 9.3.11.Spain
      • 9.3.11.1.Spain market size and forecast, by indication
      • 9.3.11.2.Spain market size and forecast, by type
      • 9.3.11.3.Spain market size and forecast, by dosage form
      • 9.3.11.4.Spain market size and forecast, by distribution channel
      • 9.3.11.5.Spain market size and forecast, by therapeutic class
    • 9.3.12.Poland
      • 9.3.12.1.Poland market size and forecast, by indication
      • 9.3.12.2.Poland market size and forecast, by type
      • 9.3.12.3.Poland market size and forecast, by dosage form
      • 9.3.12.4.Poland market size and forecast, by distribution channel
      • 9.3.12.5.Poland market size and forecast, by therapeutic class
    • 9.3.13.Rest of Europe
      • 9.3.13.1.Rest of Europe market size and forecast, by indication
      • 9.3.13.2.Rest of Europe market size and forecast, by type
      • 9.3.13.3.Rest of Europe market size and forecast, by dosage form
      • 9.3.13.4.Rest of Europe market size and forecast, by distribution channel
      • 9.3.13.5.Rest of Europe market size and forecast, by therapeutic class
  • 9.4.Asia-Pacific
    • 9.4.1.Asia-Pacific market size and forecast, by indication
    • 9.4.2.Asia-Pacific market size and forecast, by type
    • 9.4.3.Asia-Pacific market size and forecast, by dosage form
    • 9.4.4.Asia-Pacific market size and forecast, by distribution channel
    • 9.4.5.Asia-Pacific market size and forecast, by therapeutic class
    • 9.4.6.Asia-Pacific market size and forecast, by country
    • 9.4.7.Malaysia
      • 9.4.7.1.Malaysia market size and forecast, by indication
      • 9.4.7.2.Malaysia market size and forecast, by type
      • 9.4.7.3.Malaysia market size and forecast, by dosage form
      • 9.4.7.4.Malaysia market size and forecast, by distribution channel
      • 9.4.7.5.Malaysia market size and forecast, by therapeutic class
    • 9.4.8.Vietnam
      • 9.4.8.1.Vietnam market size and forecast, by indication
      • 9.4.8.2.Vietnam market size and forecast, by type
      • 9.4.8.3.Vietnam market size and forecast, by dosage form
      • 9.4.8.4.Vietnam market size and forecast, by distribution channel
      • 9.4.8.5.Vietnam market size and forecast, by therapeutic class
    • 9.4.9.Thailand
      • 9.4.9.1.Thailand market size and forecast, by indication
      • 9.4.9.2.Thailand market size and forecast, by type
      • 9.4.9.3.Thailand market size and forecast, by dosage form
      • 9.4.9.4.Thailand market size and forecast, by distribution channel
      • 9.4.9.5.Thailand market size and forecast, by therapeutic class
    • 9.4.10.Philippines
      • 9.4.10.1.Philippines market size and forecast, by indication
      • 9.4.10.2.Philippines market size and forecast, by type
      • 9.4.10.3.Philippines market size and forecast, by dosage form
      • 9.4.10.4.Philippines market size and forecast, by distribution channel
      • 9.4.10.5.Philippines market size and forecast, by therapeutic class
    • 9.4.11.Rest of Asia-Pacific
      • 9.4.11.1.Rest of Asia-Pacific market size and forecast, by indication
      • 9.4.11.2.Rest of Asia-Pacific market size and forecast, by type
      • 9.4.11.3.Rest of Asia-Pacific market size and forecast, by dosage form
      • 9.4.11.4.Rest of Asia-Pacific market size and forecast, by distribution channel
      • 9.4.11.5.Rest of Asia-Pacific market size and forecast, by therapeutic class
  • 9.5.Middle East
    • 9.5.1.Middle East market size and forecast, by indication
    • 9.5.2.Middle East market size and forecast, by type
    • 9.5.3.Middle East market size and forecast, by dosage form
    • 9.5.4.Middle East market size and forecast, by distribution channel
    • 9.5.5.Middle East market size and forecast, by therapeutic class
    • 9.5.6.Middle East market size and forecast, by country
    • 9.5.7.UAE
      • 9.5.7.1.UAE market size and forecast, by indication
      • 9.5.7.2.UAE market size and forecast, by type
      • 9.5.7.3.UAE market size and forecast, by dosage form
      • 9.5.7.4.UAE market size and forecast, by distribution channel
      • 9.5.7.5.UAE market size and forecast, by therapeutic class
    • 9.5.8.Saudi Arabia
      • 9.5.8.1.Saudi Arabia market size and forecast, by indication
      • 9.5.8.2.Saudi Arabia market size and forecast, by type
      • 9.5.8.3.Saudi Arabia market size and forecast, by dosage form
      • 9.5.8.4.Saudi Arabia market size and forecast, by distribution channel
      • 9.5.8.5.Saudi Arabia market size and forecast, by therapeutic class
    • 9.5.9.Palestine
      • 9.5.9.1.Palestine market size and forecast, by indication
      • 9.5.9.2.Palestine market size and forecast, by type
      • 9.5.9.3.Palestine market size and forecast, by dosage form
      • 9.5.9.4.Palestine market size and forecast, by distribution channel
      • 9.5.9.5.Palestine market size and forecast, by therapeutic class
    • 9.5.10.Jordan
      • 9.5.10.1.Jordan market size and forecast, by indication
      • 9.5.10.2.Jordan market size and forecast, by type
      • 9.5.10.3.Jordan market size and forecast, by dosage form
      • 9.5.10.4.Jordan market size and forecast, by distribution channel
      • 9.5.10.5.Jordan market size and forecast, by therapeutic class
    • 9.5.11.Bahrain
      • 9.5.11.1.Bahrain market size and forecast, by indication
      • 9.5.11.2.Bahrain market size and forecast, by type
      • 9.5.11.3.Bahrain market size and forecast, by dosage form
      • 9.5.11.4.Bahrain market size and forecast, by distribution channel
      • 9.5.11.5.Bahrain market size and forecast, by therapeutic class
    • 9.5.12.Qatar
      • 9.5.12.1.Qatar market size and forecast, by indication
      • 9.5.12.2.Qatar market size and forecast, by type
      • 9.5.12.3.Qatar market size and forecast, by dosage form
      • 9.5.12.4.Qatar market size and forecast, by distribution channel
      • 9.5.12.5.Qatar market size and forecast, by therapeutic class
    • 9.5.13.Azerbaijan
      • 9.5.13.1.Azerbaijan market size and forecast, by indication
      • 9.5.13.2.Azerbaijan market size and forecast, by type
      • 9.5.13.3.Azerbaijan market size and forecast, by dosage form
      • 9.5.13.4.Azerbaijan market size and forecast, by distribution channel
      • 9.5.13.5.Azerbaijan market size and forecast, by therapeutic class
    • 9.5.14.Georgia
      • 9.5.14.1.Georgia market size and forecast, by indication
      • 9.5.14.2.Georgia market size and forecast, by type
      • 9.5.14.3.Georgia market size and forecast, by dosage form
      • 9.5.14.4.Georgia market size and forecast, by distribution channel
      • 9.5.14.5.Georgia market size and forecast, by therapeutic class
    • 9.5.15.Iraq
      • 9.5.15.1.Iraq market size and forecast, by indication
      • 9.5.15.2.Iraq market size and forecast, by type
      • 9.5.15.3.Iraq market size and forecast, by dosage form
      • 9.5.15.4.Iraq market size and forecast, by distribution channel
      • 9.5.15.5.Iraq market size and forecast, by therapeutic class
    • 9.5.16.Pakistan
      • 9.5.16.1.Pakistan market size and forecast, by indication
      • 9.5.16.2.Pakistan market size and forecast, by type
      • 9.5.16.3.Pakistan market size and forecast, by dosage form
      • 9.5.16.4.Pakistan market size and forecast, by distribution channel
      • 9.5.16.5.Pakistan market size and forecast, by therapeutic class
    • 9.5.17.Kuwait
      • 9.5.17.1.Kuwait market size and forecast, by indication
      • 9.5.17.2.Kuwait market size and forecast, by type
      • 9.5.17.3.Kuwait market size and forecast, by dosage form
      • 9.5.17.4.Kuwait market size and forecast, by distribution channel
      • 9.5.17.5.Kuwait market size and forecast, by therapeutic class
    • 9.5.18.Israel
      • 9.5.18.1.Israel market size and forecast, by indication
      • 9.5.18.2.Israel market size and forecast, by type
      • 9.5.18.3.Israel market size and forecast, by dosage form
      • 9.5.18.4.Israel market size and forecast, by distribution channel
      • 9.5.18.5.Israel market size and forecast, by therapeutic class
    • 9.5.19.Kazakhstan
      • 9.5.19.1.Kazakhstan market size and forecast, by indication
      • 9.5.19.2.Kazakhstan market size and forecast, by type
      • 9.5.19.3.Kazakhstan market size and forecast, by dosage form
      • 9.5.19.4.Kazakhstan market size and forecast, by distribution channel
      • 9.5.19.5.Kazakhstan market size and forecast, by therapeutic class
    • 9.5.20.Uzbekistan
      • 9.5.20.1.Uzbekistan market size and forecast, by indication
      • 9.5.20.2.Uzbekistan market size and forecast, by type
      • 9.5.20.3.Uzbekistan market size and forecast, by dosage form
      • 9.5.20.4.Uzbekistan market size and forecast, by distribution channel
      • 9.5.20.5.Uzbekistan market size and forecast, by therapeutic class
    • 9.5.21.Tajikistan
      • 9.5.21.1.Tajikistan market size and forecast, by indication
      • 9.5.21.2.Tajikistan market size and forecast, by type
      • 9.5.21.3.Tajikistan market size and forecast, by dosage form
      • 9.5.21.4.Tajikistan market size and forecast, by distribution channel
      • 9.5.21.5.Tajikistan market size and forecast, by therapeutic class
    • 9.5.22.Kyrgyzstan
      • 9.5.22.1.Kyrgyzstan market size and forecast, by indication
      • 9.5.22.2.Kyrgyzstan market size and forecast, by type
      • 9.5.22.3.Kyrgyzstan market size and forecast, by dosage form
      • 9.5.22.4.Kyrgyzstan market size and forecast, by distribution channel
      • 9.5.22.5.Kyrgyzstan market size and forecast, by therapeutic class
    • 9.5.23.Turkmenistan
      • 9.5.23.1.Turkmenistan market size and forecast, by indication
      • 9.5.23.2.Turkmenistan market size and forecast, by type
      • 9.5.23.3.Turkmenistan market size and forecast, by dosage form
      • 9.5.23.4.Turkmenistan market size and forecast, by distribution channel
      • 9.5.23.5.Turkmenistan market size and forecast, by therapeutic class
    • 9.5.24.Rest of Middle East
      • 9.5.24.1.Rest of Middle East market size and forecast, by indication
      • 9.5.24.2.Rest of Middle East market size and forecast, by type
      • 9.5.24.3.Rest of Middle East market size and forecast, by dosage form
      • 9.5.24.4.Rest of Middle East market size and forecast, by distribution channel
      • 9.5.24.5.Rest of Middle East market size and forecast, by therapeutic class
  • 9.6.North Africa
    • 9.6.1.North Africa market size and forecast, by indication
    • 9.6.2.North Africa market size and forecast, by type
    • 9.6.3.North Africa market size and forecast, by dosage form
    • 9.6.4.North Africa market size and forecast, by distribution channel
    • 9.6.5.North Africa market size and forecast, by therapeutic class
    • 9.6.6.North Africa market size and forecast, by country
    • 9.6.7.Egypt
      • 9.6.7.1.Egypt market size and forecast, by indication
      • 9.6.7.2.Egypt market size and forecast, by type
      • 9.6.7.3.Egypt market size and forecast, by dosage form
      • 9.6.7.4.Egypt market size and forecast, by distribution channel
      • 9.6.7.5.Egypt market size and forecast, by therapeutic class
    • 9.6.8.Morocco
      • 9.6.8.1.Morocco market size and forecast, by indication
      • 9.6.8.2.Morocco market size and forecast, by type
      • 9.6.8.3.Morocco market size and forecast, by dosage form
      • 9.6.8.4.Morocco market size and forecast, by distribution channel
      • 9.6.8.5.Morocco market size and forecast, by therapeutic class
    • 9.6.9.Tunisia
      • 9.6.9.1.Tunisia market size and forecast, by indication
      • 9.6.9.2.Tunisia market size and forecast, by type
      • 9.6.9.3.Tunisia market size and forecast, by dosage form
      • 9.6.9.4.Tunisia market size and forecast, by distribution channel
      • 9.6.9.5.Tunisia market size and forecast, by therapeutic class
    • 9.6.10.Algeria
      • 9.6.10.1.Algeria market size and forecast, by indication
      • 9.6.10.2.Algeria market size and forecast, by type
      • 9.6.10.3.Algeria market size and forecast, by dosage form
      • 9.6.10.4.Algeria market size and forecast, by distribution channel
      • 9.6.10.5.Algeria market size and forecast, by therapeutic class
    • 9.6.11.Lybia
      • 9.6.11.1.Lybia market size and forecast, by indication
      • 9.6.11.2.Lybia market size and forecast, by type
      • 9.6.11.3.Lybia market size and forecast, by dosage form
      • 9.6.11.4.Lybia market size and forecast, by distribution channel
      • 9.6.11.5.Lybia market size and forecast, by therapeutic class
    • 9.6.12.Rest of North Africa
      • 9.6.12.1.Rest of North Africa market size and forecast, by indication
      • 9.6.12.2.Rest of North Africa market size and forecast, by type
      • 9.6.12.3.Rest of North Africa market size and forecast, by dosage form
      • 9.6.12.4.Rest of North Africa market size and forecast, by distribution channel
      • 9.6.12.5.Rest of North Africa market size and forecast, by therapeutic class
  • 9.7.Rest of world
    • 9.7.1.Rest of the World market size and forecast, by indication
    • 9.7.2.Rest of the World market size and forecast, by type
    • 9.7.3.Rest of the World market size and forecast, by dosage form
    • 9.7.4.Rest of the World market size and forecast, by distribution channel
    • 9.7.5.Rest of the World market size and forecast, by therapeutic class
    • 9.7.6.Rest of the World market size and forecast, by country
    • 9.7.7.Brazil
      • 9.7.7.1.Brazil market size and forecast, by indication
      • 9.7.7.2.Brazil market size and forecast, by type
      • 9.7.7.3.Brazil market size and forecast, by dosage form
      • 9.7.7.4.Brazil market size and forecast, by distribution channel
      • 9.7.7.5.Brazil market size and forecast, by therapeutic class
    • 9.7.8.Others
      • 9.7.8.1.Others market size and forecast, by indication
      • 9.7.8.2.Others market size and forecast, by type
      • 9.7.8.3.Others market size and forecast, by dosage form
      • 9.7.8.4.Others market size and forecast, by distribution channel
      • 9.7.8.5.Others market size and forecast, by therapeutic class

CHAPTER 10:COMPANY PROFILES

  • 10.1.ABBVIE Inc. (ALLERGAN PLC)
    • 10.1.1.Company overview
    • 10.1.2.Company snapshot
    • 10.1.3.Operating business segments
    • 10.1.4.Product portfolio
    • 10.1.5.Business performance
    • 10.1.6.Key strategic moves and developments
  • 10.2.Alcon, Inc.
    • 10.2.1.Company overview
    • 10.2.2.Company snapshot
    • 10.2.3.Operating business segments
    • 10.2.4.Product portfolio
    • 10.2.5.Business performance
    • 10.2.6.Key strategic moves and developments
  • 10.3.BAUSCH & LOMB INCORPORATED
    • 10.3.1.Company overview
    • 10.3.2.Company snapshot
    • 10.3.3.Operating business segments
    • 10.3.4.Product portfolio
    • 10.3.5.Business performance
    • 10.3.6.Key strategic moves and developments
  • 10.4.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)
    • 10.4.1.Company overview
    • 10.4.2.Company snapshot
    • 10.4.3.Operating business segments
    • 10.4.4.Product portfolio
    • 10.4.5.Business performance
    • 10.4.6.Key strategic moves and developments
  • 10.5.NOVARTIS AG
    • 10.5.1.Company overview
    • 10.5.2.Company snapshot
    • 10.5.3.Operating business segments
    • 10.5.4.Product portfolio
    • 10.5.5.Business performance
    • 10.5.6.Key strategic moves and developments
  • 10.6.PFIZER INC.
    • 10.6.1.Company overview
    • 10.6.2.Company snapshot
    • 10.6.3.Operating business segments
    • 10.6.4.Product portfolio
    • 10.6.5.Business performance
    • 10.6.6.Key strategic moves and developments
  • 10.7.REGENERON PHARMACEUTICALS INC.
    • 10.7.1.Company overview
    • 10.7.2.Company snapshot
    • 10.7.3.Product portfolio
    • 10.7.4.Business performance
    • 10.7.5.Key strategic moves and developments
  • 10.8.SANTEN PHARMACEUTICAL CO., LTD
    • 10.8.1.Company overview
    • 10.8.2.Company snapshot
    • 10.8.3.Operating business segments
    • 10.8.4.Product portfolio
    • 10.8.5.Business performance
    • 10.8.6.Key strategic moves and developments
  • 10.9.SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • 10.9.1.Company overview
    • 10.9.2.Company snapshot
    • 10.9.3.Operating business segments
    • 10.9.4.Product portfolio
    • 10.9.5.Business performance
    • 10.9.6.Key strategic moves and developments
  • 10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
    • 10.10.1.Company overview
    • 10.10.2.Company snapshot
    • 10.10.3.Operating business segments
    • 10.10.4.Product portfolio
    • 10.10.5.Business performance
    • 10.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 02.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 04.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 06.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 08.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 09.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 11.GLOBAL OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 12.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 13.GLOBAL OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 14.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHER RETINAL DISORDERS , BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 15.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS , BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 17.GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 18.GLOBAL OPHTHALMIC DRUGS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.GLOBAL OPHTHALMIC DRUGS MARKET FOR PRESCRIPTION DRUGS, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 20.GLOBAL OPHTHALMIC DRUGS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.GLOBAL OPHTHALMIC DRUGS MARKET FOR OVER-THE-COUNTER DRUGS, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 22.GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 23.GLOBAL OPHTHALMIC DRUGS MARKET FOR LIQUID OPHTHALMIC DRUG FORMS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 24.GLOBAL OPHTHALMIC DRUGS MARKET FOR SOLID OPHTHALMIC DRUG FORMS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 25.GLOBAL OPHTHALMIC DRUGS MARKET FOR SEMISOLID OPHTHALMIC DRUG FORMS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 26.GLOBAL OPHTHALMIC DRUGS MARKET FOR MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 27.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHER OPHTHALMIC DRUG FORMS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 28.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 29.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 30.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 31.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 32.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 33.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 34.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 35.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 36.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 37.GLOBAL OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 38.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 39.GLOBAL OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 40.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHER RETINAL DISORDERS , BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 41.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 42.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS , BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 43.GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 44.OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 45.GLOBAL OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 46.OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 47.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 48.OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 49.GLOBAL OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 50.OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 51.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 52.GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTICS CLASS, 2019-2027 ($MILLION)
  • TABLE 53.OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 54.GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 55.OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 56.GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTION, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 57.OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 58.GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 59.OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 60.GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 61.OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 62.GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS , BY DOSAGE FORM, 2019-2027 ($MILLION)
  • TABLE 63.OPHTHALMIC DRUGS MARKET, BY REGION, 2019-2027, ($MILLION)
  • TABLE 64.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 65.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 66.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 67.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 68.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 69.NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 70.U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 71.U.S OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 72.U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 73.U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 74.U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 75.REST OF NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 76.REST OF NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 77.REST OF NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 78.REST OF NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 79.REST OF NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 80.EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 81.EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 82.EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 83.EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 84.EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 85.EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 86.GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 87.GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 88.GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 89.GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 90.GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 91.FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 92.FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 93.FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 94.FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 95.FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 96.UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 97.UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 98.UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 99.UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 100.UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 101.ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 102.ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 103.ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 104.ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 105.ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 106.SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 107.SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 108.SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 109.SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 110.SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 111.POLAND OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 112.POLAND OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 113.POLAND OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 114.POLAND OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 115.POLAND OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 116.REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 117.REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 118.REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 119.REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 120.REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 121.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 122.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 123.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 124.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 125.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 126.ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 127.MALAYSIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 128.MALAYSIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 129.MALAYSIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 130.MALAYSIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 131.MALAYSIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 132.VIETNAM OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 133.VIETNAM OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 134.VIETNAM OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 135.VIETNAM OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 136.VIETNAM OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 137.THAILAND OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 138.THAILAND OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 139.THAILAND OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 140.THAILAND OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 141.THAILAND OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 142.PHILIPPINES OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 143.PHILIPPINES OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 144.PHILIPPINES OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 145.PHILIPPINES OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 146.PHILIPPINES OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 147.REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 148.REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 149.REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 150.REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 151.REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 152.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 153.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 154.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 155.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 156.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 157.MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 158.UAE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 159.UAE OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 160.UAE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 161.UAE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 162.UAE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 163.SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 164.SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 165.SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 166.SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 167.SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 168.PALESTINE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 169.PALESTINE OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 170.PALESTINE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 171.PALESTINE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 172.PALESTINE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 173.JORDAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 174.JORDAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 175.JORDAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 176.JORDAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 177.JORDAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 178.BAHRAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 179.BAHRAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 180.BAHRAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 181.BAHRAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 182.BAHRAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 183.QATAR OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 184.QATAR OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 185.QATAR OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 186.QATAR OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 187.QATAR OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 188.AZEBAIJAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 189.AZEBAIJAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 190.AZEBAIJAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 191.AZEBAIJAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 192.AZEBAIJAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 193.GEORGIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 194.GEORGIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 195.GEORGIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 196.GEORGIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 197.GEORGIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 198.IRAQ OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 199.IRAQ OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 200.IRAQ OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 201.IRAQ OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 202.IRAQ OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 203.PAKISTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 204.PAKISTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 205.PAKISTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 206.PAKISTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 207.PAKISTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 208.KUWAIT OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 209.KUWAIT OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 210.KUWAIT OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 211.KUWAIT OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 212.KUWAIT OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 213.ISRAEL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 214.ISRAEL OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 215.ISRAEL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 216.ISRAEL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 217.ISRAEL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 218.KAZAKHSTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 219.KAZAKHSTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 220.KAZAKHSTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 221.KAZAKHSTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 222.KAZAKHSTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 223.UZBEKISTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 224.UZBEKISTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 225.UZBEKISTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 226.UZBEKISTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 227.UZBEKISTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 228.TAJIKISTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 229.TAJIKISTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 230.TAJIKISTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 231.TAJIKISTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 232.TAJIKISTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 233.KYRGYZSTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 234.KYRGYZSTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 235.KYRGYZSTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 236.KYRGYZSTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 237.KYRGYZSTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 238.TURKMENISTAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 239.TURKMENISTAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 240.TURKMENISTAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 241.TURKMENISTAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 242.TURKMENISTAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 243.REST OF MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 244.REST OF MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 245.REST OF MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 246.REST OF MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 247.REST OF MIDDLE EAST OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 248.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 249.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 250.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 251.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 252.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 253.NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 254.EGYPT OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 255.EGYPT OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 256.EGYPT OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 257.EGYPT OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 258.EGYPT OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 259.MOROCCO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 260.MOROCCO OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 261.MOROCCO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 262.MOROCCO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 263.MOROCCO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 264.TUNISIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 265.TUNISIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 266.TUNISIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 267.TUNISIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 268.TUNISIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 269.ALGERIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 270.ALGERIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 271.ALGERIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 272.ALGERIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 273.ALGERIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 274.LYBIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 275.LYBIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 276.LYBIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 277.LYBIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 278.LYBIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 279.REST OF NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 280.REST OF NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 281.REST OF NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 282.REST OF NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 283.REST OF NORTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 284.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 285.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 286.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 287.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 288.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 289.REST OF THE WORLD OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 290.BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 291.BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 292.BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 293.BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 294.BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 295.OTHERS OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019-2027, ($MILLION)
  • TABLE 296.OTHERS OPHTHALMIC DRUGS MARKET, BY TYPE, 2019-2027, ($MILLION)
  • TABLE 297.OTHERS OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2019-2027, ($MILLION)
  • TABLE 298.OTHERS OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 299.OTHERS OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2019-2027, ($MILLION)
  • TABLE 300.ABBVIE: COMPANY SNAPSHOT
  • TABLE 301.ABBVIE: OERATING SEGMENT
  • TABLE 302.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 303.ALCON INC.: COMPANY SNAPSHOT
  • TABLE 304.ALCON INC.: OPERATING SEGMENTS
  • TABLE 305.ALCON INC.: PRODUCT PORTFOLIO
  • TABLE 306.BAUSCH HEALTH: COMPANY SNAPSHOT
  • TABLE 307.BAUSCH HEALTH: OERATING SEGMENT
  • TABLE 308.BAUSCH HEALTH: PRODUCT PORTFOLIO
  • TABLE 309.ROCHE: COMPANY SNAPSHOT
  • TABLE 310.ROCHE : OPERATING SEGMENTS
  • TABLE 311.ROCHE : PRODUCT PORTFOLIO
  • TABLE 312.ROCHE : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 313.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 314.NOVARTIS: OERATING SEGMENT
  • TABLE 315.NOVARTIS : PRODUCT PORTFOLIO
  • TABLE 316.PFIZER: COMPANY SNAPSHOT
  • TABLE 317.PFIZER: OERATING SEGMENT
  • TABLE 318.PFIZER: PRODUCT PORTFOLIO
  • TABLE 319.REGENERON: COMPANY SNAPSHOT
  • TABLE 320.REGENERON: PRODUCT PORTFOLIO
  • TABLE 321.SANTEN: COMPANY SNAPSHOT
  • TABLE 322.SANTEN: OERATING SEGMENT
  • TABLE 323.SANTEN: PRODUCT PORTFOLIO
  • TABLE 324.SUN PHARMA: COMPANY SNAPSHOT
  • TABLE 325.SUN PHARMA: OERATING SEGMENT
  • TABLE 326.SUN PHARMA: PRODUCT PORTFOLIO
  • TABLE 327.TEVA: COMPANY SNAPSHOT
  • TABLE 328.TEVA: OERATING SEGMENT
  • TABLE 329.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL OPHTHALMIC DRUG MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2020
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2019
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDER, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR LIQUID OPHTHALMIC DRUG FORMS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR SOLID OPHTHALMIC DRUG FORMS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR SEMISOLID OPHTHALMIC DRUG FORMS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHER OPHTHALMIC DRUG FORMS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDER, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 30.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 31.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 33.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 34.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 35.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTION, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 36.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 37.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 38.COMPARATIVE ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 39.ABBVIE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 40.ABBVIE: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 41.ABBVIE: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 42.ALCON: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.ALCON: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 44.ALCON: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 45.BAUSCH HEALTH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.BAUSCH HEALTH: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 47.BAUSCH HEALTH: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 48.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 49.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 50.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 51.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 53.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 54.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 55.PFIZER: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 56.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 57.REGENERON: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 58.SANTEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 59.SUN PHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 60.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 61.SUN PHARMA: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 62.TEVA: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 63.TEVA: REVENUE SHARE, BY SEGMENT, 2018 (%)
  • FIGURE 64.TEVA: REVENUE SHARE, BY REGION, 2018 (%)